Alignment Healthcare (NASDAQ:ALHC) reported a non-discretionary stock sale by Chief Financial Officer James M. Head, who transferred 11,100 shares of common stock on April 7, 2026, at a per-share price of $21.08. The proceeds of the sale total approximately $233,987, and were used to cover tax withholding obligations arising from the vesting of restricted stock units, according to a Form 4 filed with the Securities and Exchange Commission.
At the time of filing, the company's shares were trading at $21.31, giving Alignment Healthcare a market capitalization of roughly $4.35 billion. The stock has advanced 19.5% over the past week.
The filing makes clear that Head's transaction was executed solely to satisfy tax-withholding requirements and was not a discretionary sale. After completing the transaction, Head directly holds 173,495 shares of Alignment Healthcare common stock.
Analyst coverage compiled by InvestingPro indicates expectations that the company will return to profitability this year, with an EPS forecast of $0.46. Investors seeking additional detail can access Pro Research Reports that include ALHC alongside coverage of more than 1,400 other U.S. equities.
Alongside the insider filing, Alignment Healthcare has been active on other fronts. An affiliate of General Atlantic, L.P. has announced a secondary offering of 13.2 million shares priced at $19.46 apiece. The company stated it will not receive any proceeds from that sale, which is expected to close in March 2026, and J.P. Morgan is serving as the underwriter.
Alignment Healthcare's fourth-quarter results have also been notable. The company reported a 25% year-over-year increase in membership and a 44.4% rise in revenue, outpacing expectations. The reported medical benefit ratio was 87.7%, and management cited improvements in the selling, general, and administrative expense ratio. Following those results, Raymond James reiterated a Strong Buy rating with a $27.00 price target, while Piper Sandler maintained an Overweight rating and a $30.00 price target, both citing the stronger-than-expected fourth-quarter 2025 performance.
These developments - the CFO's RSU-related share sale, the pending secondary offering by a General Atlantic affiliate, and the company's fourth-quarter operating and financial metrics - form the most recent publicly disclosed activities surrounding Alignment Healthcare.
Summary of the filing and company activity is based on the Form 4 disclosure and the company's announcements and analyst coverage noted above.